KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Investing Activities (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Cash from Investing Activities data on record, last reported at -$85000.0 in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 466.67% year-over-year to -$85000.0; the TTM value through Dec 2025 reached -$562000.0, down 253.46%, while the annual FY2025 figure was -$562000.0, 253.46% down from the prior year.
  • Cash from Investing Activities reached -$85000.0 in Q4 2025 per AQST's latest filing, up from -$235000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$2000.0 in Q1 2023 and bottomed at -$1.7 million in Q3 2022.
  • Average Cash from Investing Activities over 5 years is -$257650.0, with a median of -$103500.0 recorded in 2021.
  • Peak YoY movement for Cash from Investing Activities: plummeted 1968.67% in 2022, then soared 98.08% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$533000.0 in 2021, then soared by 95.12% to -$26000.0 in 2022, then soared by 38.46% to -$16000.0 in 2023, then rose by 6.25% to -$15000.0 in 2024, then crashed by 466.67% to -$85000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$85000.0 in Q4 2025, -$235000.0 in Q3 2025, and -$107000.0 in Q2 2025.